Pharmacare recognizes compounded prescriptions as rational combinations of active ingredients requiring professional judgment and technical skill in their preparation.
PharmaCare reimburses pharmacies for specific compounds and for compounding costs, up to certain limits.
On this page:
PharmaCare covers other types of compounds (i.e., not on the list below) only if Special Authority approval is in place before the compound is dispensed.
If you are unsure if PharmaCare will cover a specific compound, contact the PharmaCare Help Desk before submitting the claim in PharmaNet.
Eligible compound | Criteria for coverage |
---|---|
Oral solutions | N/A |
Oral suspensions | Oral suspensions are a benefit only:
Pharmacists must document on the original prescription the reason the client requires a suspension. |
Dermatological compounds | Dermatological compounds are a benefit when all of the following conditions are met:
|
Topical antifungals | Topical antifungal compounds are a benefit only if the client has a current Special Authority for the specific active ingredient |
Retinoic acid | Retinoic acid compounds are a benefit only if the client has Special Authority approval for the specific active ingredient
|
Preservative-free sterile eye drops | Preservative-free sterile eye drops are a benefit when:
|
Plan P injectable analgesics: continuous ambulatory delivery device (CADD) pumps | The required repackaging of a prescribed injectable Plan P benefit medication(s) into a CADD pump is a compound benefit when the client is registered for Plan P |
Plan P intrathecal analgesics | Intrathecal analgesic compounds are a benefit for clients registered for Plan P |
Eligible active ingredient | Coverage criteria |
---|---|
Anthralin | For psoriasis, eczema, and other severe dermatological conditions |
Camphor | Only when in combination with at least one prescription benefit ingredient |
Clindamycin in Duonalc™ | Only clindamycin in Duonalc™ is a benefit; clindamycin in Reversa™ or any other over‑the-counter medicated base is not a benefit |
Coal tar | None |
Corticosteroids | Only when used as additives or as a medicated benefit base (e.g., hydrocortisone, betamethasone, clobetasol). Preparations containing a corticosteroid compounded with a non-benefit or over‑the‑counter medicated product are not benefits. |
Erythromycin | None |
Liquor Carbonis Detergens (LCD) | None |
Menthol | Only in combination with at least one prescription benefit ingredient |
Metronidazole | None |
Salicylic acid | For psoriasis, eczema, and other severe dermatological conditions |
Sulfur, sulfacetamide | When added to, or combined with, a medicated benefit base |
If a non-medicated base is not listed below, contact the PharmaCare Help Desk before submitting a claim.
PharmaCare does not cover compounds containing non-benefit ingredients. If a compound is not eligible for PharmaCare coverage but is claimed using a PIN for a benefit compound, the claim is subject to recovery.
PharmaCare does not cover compounds intended to replace commercially available products that have been discontinued by the manufacturer, even if the commercial product was a benefit.
Special Authority coverage for compounds to replace discontinued products may be requested only after the client’s practitioner has:
PharmaCare does not automatically cover compounds intended to replace products unavailable due to a manufacturer shortage. When notified of a shortage, PharmaCare will first verify the shortage and expected duration of the shortage with the manufacturer.
If a shortage is expected to last for an extended period of time, PharmaCare normally establishes a specific PIN and maximum price in PharmaNet for replacement compounds. Replacement compounds can then be claimed using these PINs for the duration of the shortage. The submission of Special Authority requests is not required if a specific PIN has been assigned. The PIN assigned must be in place before a claim is submitted.
If PharmaCare has not assigned a PIN for a replacement compound, prior Special Authority approval is required.
Refer to Drug shortages for information about current drug shortages and substitutions.
PharmaCare recognizes that there may be exceptional, last-resort circumstances that justify coverage of non‑benefit compounds. Special Authority approval is required for PharmaCare coverage of non-benefit compound prescriptions.
Such requests are reviewed on a case-by-case basis. PharmaCare may approve full, partial or no coverage. If Special Authority coverage for a compound is approved, PharmaCare provides the pharmacy with a specific PIN that must be used when submitting the claim.
Pharmacies are required to submit a HLTH 5425 - Compound Costing Worksheet (PDF, 521KB) for compounds that require Special Authority approval. A copy of the approved Compound Costing Worksheet must be retained on file with the original prescription.
Refer to Submitting a Special Authority request for a compound at the end of this section.
The maximum allowable compounding fees that PharmaCare will reimburse are specified in the table below. If a compound does not appear in the table below, PharmaCare Special Authority will review compounding costs on a case-by-case basis and determine an appropriate compounding fee.
Compounding fees must be added to the ingredient costs, and the combined amount entered in the Drug Cost field in PharmaNet. Do not include the compounding fee in the Dispensing Fee field.
Compounding fees in excess of PharmaCare maximums—or the amount approved by Special Authority—must not be claimed in the Drug Cost field. Upcharges on compounding fees must be entered in the Cost Upcharge field so that the amount becomes payable by the client or their alternate insurer.
The table below lists maximum fees for both benefit compounds and compounds approved by Special Authority that would otherwise be a non-benefit. The inclusion of a fee for a particular type of compound, therefore, does not necessarily mean benefit status.
Compound | Maximum allowable compound fee |
Oral solutions | $20.00 |
Oral suspensions | $20.00 |
Capsules | $0.30 per capsule |
Suppositories | $40.00 * |
Oral lozenges | $40.00 * |
CADD injections | $20.00 |
Sterile IV, IM, SC injections | $20.00 |
Intrathecal injections | $40.00 |
Creams/ointments/lotions < or = 250 gm/mL | $15.00 |
Creams/ointments/lotions > or = 251 gm/mL | $20.00 |
Sterile eye drops, preservative-free | $30.00 |
* Where appropriate (e.g., when the prescription will be dispensed on a frequent, short days’ supply basis), the compounding fee for suppositories and oral lozenges will be pro-rated during Special Authority adjudication.
Pharmacies can claim both their usual dispensing fee and a compounding fee.
Ingredient costs for compounds are subject to all PharmaCare Pricing Policies.
Ingredient costs for commercial products must be claimed at the lowest of any pricing policy applicable to the product (e.g., the Maximum Pricing Policy, Low Cost Alternative Program, Reference Drug Program).
Raw ingredients are subject to the Actual Acquisition Cost Policy.
PharmaCare expects pharmacies to use the most reasonably priced ingredients when compounding PharmaCare benefits. For example:
PharmaCare covers the cost of the following supplies and equipment:
Reimbursement for eligible supplies and equipment is subject to the Actual Acquisition Cost Policy.
PharmaCare does not cover these costs:
Enter claims for prescription compounds using the applicable benefit or non-benefit compound PIN.
Claims for non-benefit compounds that are submitted using a PIN for a benefit compound are subject to recovery.
When Special Authority coverage for a compound is approved, PharmaCare will provide the pharmacy with a specific PIN for use when submitting the claim. Pharmacists must use that specific PIN when submitting the claim to PharmaNet.
Refer to Compounded Prescriptions PINs for the list of PINs.
When a pharmacy contracts another pharmacy to provide a compound for individual prescriptions, the dispensing pharmacy may not claim more than is permitted under the PharmaCare Compounded Prescriptions policy.
When determining if contracting this service is appropriate, the dispensing pharmacy should ensure the contracted pharmacy will provide the compound at a cost within PharmaCare policy limits.
If a pharmacy contracts another pharmacy to provide a compound, the pharmacy must ask the compounding pharmacy for a cost breakdown and must retain that cost breakdown on file in keeping with the recordkeeping requirements below.
For benefit compounds, pharmacies must document the following information and retain it on file with the original prescription:
This information may be recorded on the prescription or on a separate document attached to the prescription. The HLTH 5425 - Compound Costing Worksheet (PDF, 521KB) may be used for this purpose.
If a change in costs occurs for a refill of a compound, pharmacies must complete and retain a new compound costing document, including all the information above.
For compounds requiring Special Authority, pharmacies must retain on file with the original prescription a copy of the SA-approved HLTH 5425 - Compound Costing Worksheet (PDF, 521KB).
When submitting a claim for a compound:
Do not add the compounding fee to the Dispensing Fee field.
BENEFIT COMPOUND SUSPENSIONS |
|
---|---|
Benefit compound PINs are drug/dosage form specific. To ensure the dose and concentration is visible to other PharmaNet users, enter it exactly as indicated in the example below: |
|
Prescription |
felodipine 10 mg (in suspension) once daily. |
PIN |
22123241 |
Description in PharmaNet |
felodipine compounded suspension |
Directions for SIG field |
Take 5 mL (10 mg) once daily |
PALLIATIVE BENEFIT CADD PUMP COMPOUNDS |
|
CADD pump PINs specify whether or not the ingredient is narcotic. The dose is usually included in the directions of the prescription. To identify the specific drug being used, enter it exactly as indicated in the example below. |
|
Prescription |
hydromorphone 20 mg/mL for CADD. 3.5 mg/hr and 7 mg BTP q20min |
PIN |
22123288 |
Description in PharmaNet |
narcotic CADD pump compound: palliative |
Directions for SIG field |
Run 3.5 mg/hr (hydromorphone) and 7 mg for BTP every 20 min. |
BENEFIT DERMATOLOGICAL COMPOUNDS |
|
PINs for these medications identify the ingredient or class of ingredients. Pharmacists are not required to enter the specific corticosteroid or concentration of ingredients. Example below. |
|
Prescription |
HC 1% + menthol 0.25% cream. BID |
PIN |
22123278 |
Description in PharmaNet |
corticosteroid + menthol +/or camphor |
Directions for SIG field |
Enter usual directions for use. |
BENEFIT COMPOUNDED PRESERVATIVE-FREE EYEDROPS |
|
---|---|
PINS for eyedrops identify the active ingredient and that the eyedrops are preservative-free. Add the concentration of the eyedrops to the directions as indicated in the example below. |
|
Prescription |
timolol 0.25% preservative-free eyedrops. 1 gtt BID. |
PIN |
22123295 |
Description in PharmaNet |
timolol PF cpd eyedrop |
Directions for SIG field |
Instil 1 drop (0.25%) in left eye twice daily. |
PALLIATIVE BENEFIT COMPOUNDED INTRATHECAL INJECTIONS |
|
Due to wide variation in ingredients and concentration of ingredients, the PINs give only a general description. It is not necessary to add information to the usual instructions for use. Example below. |
|
Prescription |
intrathecal fentanyl 1000 mcg + bupivicaine 40 mcg + clonidine 100 mcg/mL |
PIN |
22123302 |
Description in PharmaNet |
narcotic + non-narcotic intrathecal cpd: palliative |
Directions for SIG field |
Enter usual directions for use. |
Retain the original prescription and supporting documentation on file (refer to Recordkeeping Requirements).
To obtain Special Authority approval for coverage, the following documentation is needed:
From a medical practitioner:
For certain palliative care compounds, a copy of the prescription may suffice as supporting documentation. Contact the PharmaCare Help Desk to determine the documents required.
From a pharmacy:
When PharmaCare receives the Special Authority Request and cost breakdown, it will decide the amount, if any, that is eligible for PharmaCare coverage.
PharmaCare will advise the:
If a pharmacy submits multiple claims for compounded prescriptions on the same day using the same PIN for different preparations for the same PHN, PharmaNet cannot determine that they are separate prescriptions and will reject them because it will interpret them as an error. To prevent rejection of multiple same-day/same PHN claims for compounds, submit the claim with the Intervention Code UF – Patient Gave Adequate Explanation.